In addition,norovirusoutbreaks may be the most common foodborne illness outbreaks. Noroviruses can cause extended outbreaks because of their high infectivity, persistence in the environment, resistance to common disinfectants, and difficulty in controlling their transmission through routine sanitary measures.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs uniquestructure-based technologies to create viable antiviral drugs.
This press release contains forward-looking statements within the meaning of the Private SecuritiesLitigationReform Act of 1995, including statements regarding any implications that CDI-988 is able to prevent and/or treatnorovirusinfections.
As we can see from the illustration, Norovirus Litigation Nutmeg Structure Proceed has many fascinating aspects to explore.
This press release contains forward-looking statements within the meaning of the Private SecuritiesLitigationReform Act of 1995, including statements regarding our initiation of thenorovirusstudy in the first quarter of 2026 and the potential of CDI-988 fornorovirusinfections.
This press release contains forward-looking statements within the meaning of the Private SecuritiesLitigationReform Act of 1995, including statements regarding any implications that ...
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment ofNorovirusInfection
Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private SecuritiesLitigationReform Act of 1995, including statements regarding any implications that CDI-988 is able to prevent and/or treatnorovirusinfections.
